Please login to the form below

Not currently logged in

Pfizer and Astellas co-promote Caduet

Pfizer Japan and Astellas have agreed to co-promote a combination hypertension and hypercholesterolemia drug in Japan

The treatment, Caduet Combination Tablets, is an oral combination of Pfizer's hypertension treatment, Norvasc (amlodipine besylate) and hypercholesterolemia drug, Lipitor (atorvastatin calcium). The single tablet combination is expected to improve patient adherence.

Under the terms of the agreement (which lasts until July 2016), Pfizer will manufacture the combination treatment and be responsible for sales, while both companies will promote it.

The companies have worked together previously and co-promote Lipitor. Caduet Combination Tablets are approved in more than 70 countries/areas and will be available in Japan once listed on Japan's National Health Insurance drug price list.

26th August 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...